FONDAZIONE
PER LA RICERCA FARMACOLOGICA
GIANNI BENZI
ONLUS

COVID-19 vaccines under evaluation

The **Human Medicines Committee (CHMP) at EMA** is evaluating preliminary data on the following COVID-19 candidate vaccines

Vaccine	Developer	Description	Status	Start of the evaluation	PIP number	More information
VLA2001	Valneva	VLA2001 contains inactivated SARS-CoV-2 that cannot cause the disease. It also contains two 'adjuvants', substances to help strengthen the immune response to the vaccine. When a person is given the vaccine, their immune system identifies the inactivated virus as foreign and makes antibodies against it. If, later on, the vaccinated person comes into contact with SARS-CoV-2, the immune system will recognise the virus and be ready to defend against it	Rolling review	02/12/2021	-	https://www.ema.europa.eu/en/news/ema-starts-rolling-review-valnevas-covid-19-vaccine-vla2001
Vidprevtyn	Sanofi Pasteur	Vidprevtyn is a protein-based vaccine that contains a laboratory-grown version of the spike protein found on the surface of SARS-CoV-2. It also contains an 'adjuvant', a substance to help strengthen the immune responses to the vaccine. When a person is given the vaccine, their immune system identifies the spike protein as foreign and	Rolling review	20/07/2021	-	https://www.ema.europa.eu/en/news/ema-starts-rolling-review-covid-19-vaccine-vidprevtyn

Vaccine	Developer	Description	Status	Start of the evaluation	PIP number	More information
		makes antibodies against it. If, later, the vaccinated person comes into contact with SARS-CoV-2, the immune system will recognise the viral protein and be ready to defend the body against the virus				
COVID-19 Vaccine (Vero Cell) Inactivated	Sinovac Life Sciences Co., Ltd	COVID-19 Vaccine (Vero Cell) Inactivated contains SARS-CoV-2 that has been inactivated and cannot cause the disease. The vaccine also contains an 'adjuvant' that helps strengthen the immune response to the vaccine. When a person is given the vaccine, their immune system identifies the inactivated virus as foreign and makes antibodies against it. If, later, the vaccinated person comes into contact with SARS-CoV-2, the immune system will recognise the virus and be ready to defend the body against it	Rolling review	04/05/2021	-	https://www.ema.europa.eu/en/news/ema-starts-rolling-review-covid-19-vaccine-vero-cell-inactivated

Vaccine	Developer	Description	Status	Start of the evaluation	PIP number	More information
Sputnik V (Gam-COVID-Vac)	Russia's Gamaleya National Centre of Epidemiology and Microbiology	Sputnik V is made up of two different viruses belonging to the adenovirus family, Ad26 and Ad5. These adenoviruses have been modified to contain the gene for making the SARS-CoV-2 spike protein; they cannot reproduce in the body and do not cause disease. The two adenoviruses are given separately: Ad26 is used in the first dose and Ad5 is used in the second one to boost the vaccine's effect. Once it has been given, the vaccine delivers the SARS-CoV-2 gene into cells in the body. The cells will use the gene to produce the spike protein. The immune system will treat this spike protein as foreign and produce antibodies and T cells against this protein. If, later on, the vaccinated person comes into contact with the virus, the immune system will recognise the spike protein on the virus and be prepared to attack it	Rolling review	04/03/2021	-	https://www.ema.europa.eu/en/news/ema-starts-rolling-review-sputnik-v-covid-19-vaccine

Vaccine	Developer	Description	Status	Start of the evaluation	PIP number	More information
CVnCoV	CureVac AG	CVnCoV contains a molecule called messenger RNA (mRNA) which has instructions for making the spike protein of the SARS-CoV-2 virus. The mRNA is contained in tiny particles of lipids that prevent it from being broken down too quickly. When a person is given the vaccine, some of their cells will read the mRNA instructions and temporarily produce the spike protein. The immune system will then recognise this protein as foreign and produce antibodies and activate T cells against it. If, later on, the person comes into contact with the virus, the immune system will recognise the protein and be ready to defend the body against the virus. The mRNA from the vaccine is broken down shortly after vaccination	Withdrawn from rolling review on 12/10/2021	12/02/2021	EMEA-002986-PIP01-21	• https://www.ema.europa.eu/en/news/ema-starts-rolling-review-curevacs-covid-19-vaccine-cvncov • https://www.ema.europa.eu/en/news/ema-ends-rolling-review-cvncov-covid-19-vaccine-following-withdrawal-curevac-ag